King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Amani AlKofide
Dr. Amani AlKofide is a Consultant Paediatric Haematologist/Oncologist specialising in paediatric solid tumours including neuroblastoma, hepatoblastoma, rhabdomyosarcoma, and atypical teratoid rhabdoid tumours (ATRT) — a trusted paediatric oncologist in Riyadh, Saudi Arabia providing multidisciplinary care to international families. She serves on an international Editorial Board in hematology, oncology and stem cell therapy and is an active academic faculty member in paediatric oncology training.
- Consultant Paediatric Oncologist with 20+ years experience in paediatric solid tumours
- Academic faculty member — paediatric oncology training and medical education
- Editorial Board member for a leading hematology, oncology and stem cell therapy journal
- Published researcher on hepatoblastoma, high-risk neuroblastoma, ATRT, and rhabdomyosarcoma outcomes
- Lead contributor to Saudi paediatric palliative care research
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Paediatric Residency
Fellowships & Special Training
- Fellowship in Paediatric Haematology/Oncology
- Subspecialty Training in Paediatric Solid Tumours
- Paediatric Palliative Care Training
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- International Society of Paediatric Oncology (SIOP) — Member
- American Society of Clinical Oncology (ASCO) — Member
Areas of Expertise
Major Conditions Treated
- Neuroblastoma (Including High-Risk)
- Hepatoblastoma
- Rhabdomyosarcoma
- Atypical Teratoid Rhabdoid Tumour (ATRT)
- Paediatric Brain Tumours
- Wilms Tumour
- Ewing Sarcoma
- Osteosarcoma
- Retinoblastoma (Systemic Therapy)
- Germ Cell Tumours
Sub-specialties
- Paediatric Neuroblastoma: High-risk neuroblastoma treatment including induction chemotherapy, autologous stem cell rescue, 13-cis-retinoic acid, and anti-GD2 immunotherapy — an experienced paediatric oncologist in Riyadh for international families.
- Paediatric Hepatoblastoma: Multidisciplinary management combining neoadjuvant chemotherapy (PLADO, SIOPEL regimens) with surgical resection and liver transplantation referrals.
- Paediatric Palliative Oncology: Integrated palliative and supportive care for children with advanced cancer — a regional leader in paediatric palliative oncology research and practice.
Advanced Procedures & Treatments
- Induction Chemotherapy (PLADO, COJEC, VAC Regimens)
- Autologous Stem Cell Rescue for High-Risk Neuroblastoma
- Anti-GD2 Immunotherapy (Dinutuximab)
- 13-cis-Retinoic Acid Maintenance
- Rhabdomyosarcoma Risk-Stratified Therapy
- Multidisciplinary Tumour Board Management
- Paediatric Palliative & Supportive Care
- Long-Term Survivorship Follow-Up
Professional Experience
Current Affiliation
- Consultant, Paediatric Haematology/Oncology (Solid Tumours) — King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia (Present)
- Faculty — Alfaisal University College of Medicine, Riyadh (Present)
Past Affiliations
- Paediatric Haematology/Oncology Fellowship — completed prior to consultancy
Academic & Research Roles
- Faculty — Alfaisal University College of Medicine (Paediatric Oncology)
- Editorial Board — Hematology/Oncology and Stem Cell Therapy (HOSCT)
- Contributing author — multiple peer-reviewed paediatric oncology publications
Key Achievements
- Lead or co-author on Saudi hepatoblastoma experience
- Co-author on 20-year high-risk neuroblastoma outcomes study
- Co-author on Saudi paediatric rhabdomyosarcoma outcomes analysis
- Published researcher on ATRT outcomes and paediatric palliative care
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- International Society of Paediatric Oncology (SIOP)
- American Society of Clinical Oncology (ASCO)
- Saudi Paediatric Association
- Editorial Board — Hematology/Oncology and Stem Cell Therapy
Research & Publications
Published Papers (Selected)
- AlKofide A, et al. Hepatoblastoma in Children — Single Institution Experience. 2021. PMC7922831.
- AlKofide A, et al. High-Risk Neuroblastoma Outcomes — 20-Year Analysis. 2021. PMC8356102.
- AlKofide A, et al. Atypical Teratoid Rhabdoid Tumour (ATRT) in Children. 2021. PMC8319682.
- AlKofide A, et al. Paediatric Rhabdomyosarcoma — Clinical Outcomes. 2023. PMC9875671.
- AlKofide A, et al. Paediatric Palliative Care in Oncology — Saudi Experience. 2023. PMC10366288.
Ongoing Research & Clinical Interests
- High-risk neuroblastoma treatment optimisation
- Paediatric hepatoblastoma and liver tumour outcomes
- Paediatric palliative and supportive oncology
- Rare paediatric solid tumours (ATRT, rhabdoid tumours)
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Paediatric Oncology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Paediatric Chemotherapy (per cycle) | ₹25,000 – ₹1,75,000 | $300 – $2,100 |
| Paediatric Stem Cell Transplant | ₹18,00,000 – ₹35,00,000 | $21,700 – $42,200 |
| Tumour Biopsy & Molecular Profiling | ₹15,000 – ₹75,000 | $180 – $900 |
| Targeted / Immunotherapy (per cycle) | ₹80,000 – ₹3,00,000 | $960 – $3,600 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Amani AlKofide use in Paediatric Haematology / Oncology — Solid Tumours treatment?
Dr. Amani AlKofide uses advanced paediatric solid tumour technologies including risk-stratified induction chemotherapy (PLADO, COJEC, VAC regimens), autologous stem cell rescue for high-risk neuroblastoma, anti-GD2 immunotherapy (dinutuximab), 13-cis-retinoic acid maintenance therapy, multidisciplinary tumour board coordination, and integrated paediatric palliative care pathways. Virtual consultations and remote second opinions are also available to international families through Cancer Rounds.
2. What conditions does Dr. Amani AlKofide specialize in treating?
Dr. Amani AlKofide specialises in Paediatric Solid Tumour Oncology, treating neuroblastoma (including high-risk), hepatoblastoma, rhabdomyosarcoma, atypical teratoid rhabdoid tumour (ATRT), paediatric brain tumours, Wilms tumour, Ewing sarcoma, osteosarcoma, retinoblastoma requiring systemic therapy, and germ cell tumours. International families seeking the best paediatric solid tumour specialist in India or Saudi Arabia benefit from her extensive published experience.
3. How do I book an appointment with Dr. Amani AlKofide?
Appointments with Dr. Amani AlKofide can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Amani AlKofide?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Amani AlKofide, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Amani AlKofide offer second opinions for Paediatric Haematology / Oncology — Solid Tumours cases?
Yes. Second opinion consultations for Paediatric Solid Tumour cases can be arranged via Cancer Rounds, enabling international families to review complex paediatric oncology diagnoses, risk stratification, and treatment plans with Dr. Amani AlKofide.
